文献速递白血病造血干细胞移植与细胞治疗

青少年和青年急性髓系白血病患者接受单倍体相合造血干细胞移植的结局

Outcomes of haploidentical haematopoietic stem cell transplantation for adolescent and young adults with acute myeloid leukaemia.
PubMed 文献 · Br J Haematol · 2023-06-26

该研究纳入599例15-39岁完全缓解期接受单倍体相合造血干细胞移植的急性髓系白血病青少年和青年患者,3年可测量残留病发生率28.6%、复发率11.6%、非复发死亡率6.7%,无事件生存率60.7%、无白血病生存率81.7%、总生存率85.6%;诊断时AML危险分层和移植前合并症负担与无白血病生存和总生存独立相关;与同期≥40岁成人相比,青少年和青年非复发死亡率更低、无白血病生存和总生存更高。

要点

  • 15-39岁AML完全缓解期接受单倍体移植,3年总生存率85.6%、无白血病生存率81.7%。
  • 3年复发率11.6%、非复发死亡率6.7%、可测量残留病发生率28.6%。
  • 诊断时AML危险分层和移植前合并症负担与无白血病生存和总生存独立相关。

核心结论

  • 研究首次证实单倍体相合造血干细胞移植在完全缓解期青少年和青年急性髓系白血病患者中安全有效。

研究设计与样本

  • 大型队列研究,连续纳入599例15-39岁完全缓解期接受单倍体相合造血干细胞移植的急性髓系白血病青少年和青年患者。

主要发现

  • 单倍体移植后3年可测量残留病累积发生率为28.6%(95%CI:25.0-32.2)。
  • 单倍体移植后3年复发累积发生率为11.6%(95%CI:9.0-14.2),非复发死亡累积发生率为6.7%(95%CI:4.7-8.7)。
  • 单倍体移植后3年无事件生存概率为60.7%(95%CI:56.9-64.8),无白血病生存概率为81.7%(95%CI:78.7-84.9),总生存概率为85.6%(95%CI:82.8-88.4)。
  • 多因素分析中,诊断时AML危险分层和单倍体移植前合并症负担与无白血病生存和总生存独立相关。
  • 与同期接受单倍体移植的≥40岁成人(n=355)相比,青少年和青年非复发死亡率更低,无白血病生存和总生存概率更高。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We aimed to identify the efficacy of haploidentical related donor (HID) haematopoietic stem cell transplantation (HSCT) in adolescent and young adults (AYAs) with acute myeloid leukaemia (AML) in a large cohort. Consecutive AML AYAs (15-39 years old, n = 599) receiving HID HSCT in complete remission (CR) were included. The 3-year cumulative incidence of measurable residual disease occurrence, relapse and non-relapse mortality after HID HSCT was 28.6% (95% CI: 25.0-32.2), 11.6% (95% CI: 9.0-14.2) and 6.7% (95% CI: 4.7-8.7) respectively. The 3-year probability of event-free survival, leukaemia-free survival (LFS) and overall survival (OS) after HID HSCT was 60.7% (95% CI: 56.9-64.8), 81.7% (95% CI: 78.7-84.9) and 85.6% (95% CI: 82.8-88.4) respectively. In multivariable analysis, AML risk category at diagnosis and comorbidity burdens before HID HSCT were independently associated with LFS and OS. Compared to the older adults (≥ 40 years, n = 355) with AML receiving HID HSCT in CR during the same time period, AYAs have a lower incidence of non-relapse mortality and higher probabilities of LFS and OS. Thus, we firstly confirmed the safety and efficacy of HID HSCT in AYAs with AML-CR.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Huo WX, Wen Q, Zhang XH, et al. Outcomes of haploidentical haematopoietic stem cell transplantation for adolescent and young adults with acute myeloid leukaemia. Br J Haematol. 2023. PMID: 37365147. doi:10.1111/bjh.18937

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。